In a welcome move, Progyny saw its Relative Strength Rating improve from 63 to 77 on Monday.
When To Sell Stocks To Lock In Profits And Minimize Losses
This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
Over 100 years of market history shows that the best stocks typically have an RS Rating of above 80 in the early stages of their moves. See if Progyny can continue to show renewed price strength and hit that benchmark.
Progyny is working on a consolidation with a 26.76 entry. See if it can break out in heavy trading.
While earnings-per-share growth declined in the company's most recently reported quarter from 31% to 23%, sales grew 17%, up from 11% in the prior report.
The company earns the No. 2 rank among its peers in the Medical-Services industry group. Hims & Hers Health is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
